SynthesisFrontiers in immunology2024
Pan-immune inflammation value as a prognostic biomarker for cancer patients treated with immune checkpoint inhibitors.
Synthesis in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 5 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- The prognostic value of the pan-immune-inflammation value in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Prognostic value of the pretreatment pan-immune-inflammation value in patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Prognostic significance of the pretreatment pan-immune-inflammation value in colorectal cancer patients: an updated meta-analysis.Frontiers in oncology · 2025Pooled it
- Prognostic significance of prognostic nutritional index in patients with head and neck squamous cell carcinoma.Frontiers in immunology · 2025Pooled it
- The predictive value of the neutrophil/eosinophil ratio in cancer patients undergoing immune checkpoint inhibition: a meta-analysis and a validation cohort in hepatocellular carcinoma.Frontiers in immunology · 2025Pooled it
- Prognostic Significance of Inflammatory Biomarkers in First-Line Immunotherapy for Metastatic Melanoma: Multicentric Study.Cancers · 2026Article
- Prognostic Value of C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index for Survival in Nivolumab-Treated Metastatic Renal Cell Carcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Additional predictive value of systemic inflammation indices beyond prostate specific antigen density for clinically significant prostate cancer.BMC urology · 2026Article
- The potential role of pan-immune-inflammation value in differentiating pediatric osteomyelitis from soft tissue infections.Translational pediatrics · 2026Article
- Prognostic significance of the pan-immune-inflammatory value (PIV) in gastric cancer: a retrospective cohort study.BMC cancer · 2026Article
- Pan-immune inflammation value and neutrophil-to-albumin ratio predict hemorrhagic transformation after intravenous thrombolysis in acute ischemic stroke: a dual-center cohort study.Frontiers in nutrition · 2026Article
- Pan-immune-inflammation value predicts 2-year recurrence after chemoradiotherapy in nasopharyngeal carcinoma.Frontiers in medicine · 2026Article
- The relationship between pan immune inflammatory index (PIV) and 28 day mortality in patients with severe urinary sepsis: a retrospective study of a multinational dual cohort study.Frontiers in medicine · 2026Article
- Multicenter cohort study reveals: composite inflammatory indexs are associated with increased risk of diabetes in patients with hypertension.Frontiers in endocrinology · 2026Article
- Association of Life's Crucial 9 Score With Liver Fibrosis and Mortality in U.S. Adults With MASLD: Evidence From NHANES and the Mediating Role of Systemic Inflammation.Mediators of inflammation · 2026Article
- ctDNA and immune biomarker testing for molecular residual disease surveillance and immune stratification in cancer.Frontiers in medicine · 2026Review
- Combined immunoscore and pan-immune inflammation value associated with pathological response and survival outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.International journal of surgery (London, England) · 2026Article
- Association of Preoperative Pan-Immune-Inflammation Value with Adverse Pathology and Oncological Outcomes Following Radical Prostatectomy: A Single-Center Retrospective Study.International journal of medical sciences · 2026Article
- Baseline and Longitudinal Pan-Immune-Inflammation Value Compared with Other Inflammatory Indices in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Cohort Study.Sisli Etfal Hastanesi tip bulteni · 2026Article
- Diagnostic value of cellular inflammatory markers in CNS tumor patients undergoing glucocorticoid therapy.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) represent a paradigm shift in the development of cancer therapy. However, the improved efficacy of ICIs remains to be further investigated. We conducted a systematic review and meta-analysis to evaluate the pan-immunoinflammatory value (PIV) and PILE score used to predict response to ICI therapy. Methods: We searched selected databases for studies on pan-immune inflammation values and their association with outcomes of treatment with immune checkpoint inhibitors. We used hazard ratios (HRS) and 95% confidence intervals (CI) to summarize survival outcomes. All data analyses were performed using STATA 15.0. Results: 7 studies comprising 982 patients were included in the meta-analysis. The pooled results showed that higher PIV was significantly associated with shorter overall survival OS (HR = 1.895, 95%CI: 1.548-2.318) and progression-free survival (PFS) (HR = 1.582, 95%CI: 1.324-1.890). Subgroup analyses also confirmed the reliability of the results. Conclusions: High PIV and PILE metrics are associated with lower survival in cancer patients receiving ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.